Publications:

Preclinical assessment of combination therapy of EGFR tyrosine kinase inhibitors in a highly heterogeneous tumor model.

Oncogene

Ikeuchi, Hiroshi H; Hirose, Takeshi T; Ikegami, Masachika M; Takamochi, Kazuya K; Suzuki, Kenji K; Mano, Hiroyuki H; Kohsaka, Shinji S

Publication Date: 2022-04

Variant appearance in text: EGFR: N826D

PubMed Link: 35304574

Variant Present in the following documents:

• 41388_2022_Article_2263.pdf

View BVdb publication page

Formalin fixation increases deamination mutation signature but should not lead to false positive mutations in clinical practice.

Plos One

Prentice, Leah M LM; Miller, Ruth R RR; Knaggs, Jeff J; Mazloomian, Alborz A; Aguirre Hernandez, Rosalia R; Franchini, Patrick P; Parsa, Kourosh K; Tessier-Cloutier, Basile B; Lapuk, Anna A; Huntsman, David D; Schaeffer, David F DF; Sheffield, Brandon S BS

Publication Date: 2018

Variant appearance in text: EGFR: N826D

PubMed Link: 29698444

Variant Present in the following documents:

• pone.0196434.s001.xlsx, sheet 1
• pone.0196434.s001.xlsx, sheet 3
• pone.0196434.s001.xlsx, sheet 2

View BVdb publication page

EGFR mutational status in a large series of Caucasian European NSCLC patients: data from daily practice.

British Journal Of Cancer

Gahr, S S; Stoehr, R R; Geissinger, E E; Ficker, J H JH; Brueckl, W M WM; Gschwendtner, A A; Gattenloehner, S S; Fuchs, F S FS; Schulz, C C; Rieker, R J RJ; Hartmann, A A; Ruemmele, P P; Dietmaier, W W

Publication Date: 2013-10-01

Variant appearance in text: EGFR: N826D

PubMed Link: 24002608

Variant Present in the following documents:

• Main text
• bjc2013511a.pdf

View BVdb publication page